| 产品描述: | 脂肪氧化酶抑制剂;Lipoxygenase Inhibitors;产品介绍:FPL 62064 是一种 5-lipoxygenase (5-LOX) 和 prostaglandin synthetase (cyclooxygenase, COX) 的有效双重抑制剂,对RBL-1胞质5-LOX和精囊prostaglandin synthetase的IC50值分别为3.5 μM和3.1 μM。FPL 62064 具有有效的抗炎活性。;InformationFPL 62064 FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and prostaglandin synthetase (cyclooxygenase, COX) with IC50 of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and seminal vesicle prostaglandin synthetase, respectively. FPL 62064 has potent anti-inflammatory activity.Targetsseminal vesicle prostaglandin synthetase (Cell-free assay); RBL-1 cytosolic 5-LOX (Cell-free assay) 3.1 μM; 3.5 μM |
| 靶点: |
IC50: 3.5 μM (RBL-1 cytosolic 5-1ipoxygenase), and 3.1 μM (prostaglandin synthetase) |
| 体内研究: |
FPL 62064 (5-20 mg/kg; intraperitoneal injection; female LACA mice) treatment inhibits peritoneal inflammation induced by immune-complex. |
| 参考文献: |
1. Blackham A, et al. FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42. 2. Shabaan MA, et al. Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase. Arch Pharm (Weinheim). 2020 Feb 7:e1900308. |
| 保存条件: |
避光,-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.769 ml |
18.846 ml |
37.692 ml |
| 5 mM |
0.754 ml |
3.769 ml |
7.538 ml |
| 10 mM |
0.377 ml |
1.885 ml |
3.769 ml |
| 50 mM |
0.075 ml |
0.377 ml |
0.754 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |